Skip to main content
. 2012 Sep 1;13(11):1001–1008. doi: 10.4161/cbt.21188

graphic file with name cbt-13-1001-g2.jpg

Figure 2. Possible algorithm for treatment of docetaxel progressed CRPC.52 PD = progression of disease; CRPC = castration resistant prostate cancer. ECOG PS = Eastern Cooperative Oncology Group. Performance Status; RR = Response Rate. * Unlike other drugs approved for CRPC patients progressing during or after docetaxel-based chemotherapy, Sipuleucel-T has been approved for patients with metastatic, asymptomatic or minimally symptomatic, hormone-refractory prostate cancer.